Kiniksa Pharmaceuticals International (NASDAQ:KNSA) Upgraded at Zacks Research

Zacks Research upgraded shares of Kiniksa Pharmaceuticals International (NASDAQ:KNSA) from a strong sell rating to a hold rating in a research note issued to investors on Wednesday,Zacks.com reports.

Other analysts have also issued research reports about the stock. Wedbush lifted their price target on shares of Kiniksa Pharmaceuticals International from $50.00 to $53.00 and gave the company an “outperform” rating in a research report on Wednesday. Weiss Ratings reissued a “hold (c)” rating on shares of Kiniksa Pharmaceuticals International in a research note on Thursday, January 22nd. Canaccord Genuity Group assumed coverage on Kiniksa Pharmaceuticals International in a research report on Thursday, February 19th. They issued a “buy” rating and a $62.00 target price on the stock. The Goldman Sachs Group increased their price target on Kiniksa Pharmaceuticals International from $45.00 to $55.00 and gave the stock a “buy” rating in a report on Wednesday, October 29th. Finally, Wells Fargo & Company raised their price objective on Kiniksa Pharmaceuticals International from $50.00 to $53.00 and gave the stock an “overweight” rating in a research report on Wednesday. Seven research analysts have rated the stock with a Buy rating and two have issued a Hold rating to the company’s stock. According to MarketBeat.com, the stock has an average rating of “Moderate Buy” and an average price target of $55.29.

Kiniksa Pharmaceuticals International Stock Up 2.3%

NASDAQ KNSA opened at $44.49 on Wednesday. The business’s fifty day simple moving average is $42.96 and its 200-day simple moving average is $39.77. The firm has a market cap of $3.37 billion, a PE ratio of 60.12 and a beta of 0.06. Kiniksa Pharmaceuticals International has a 52 week low of $18.25 and a 52 week high of $49.12.

Kiniksa Pharmaceuticals International (NASDAQ:KNSA) last released its quarterly earnings data on Tuesday, February 24th. The company reported $0.17 earnings per share (EPS) for the quarter, missing the consensus estimate of $0.29 by ($0.12). Kiniksa Pharmaceuticals International had a return on equity of 11.48% and a net margin of 8.71%.The firm had revenue of $202.13 million for the quarter, compared to analyst estimates of $200.86 million. During the same quarter in the previous year, the business posted ($0.12) earnings per share. Kiniksa Pharmaceuticals International’s revenue for the quarter was up 65.0% on a year-over-year basis. Research analysts expect that Kiniksa Pharmaceuticals International will post -0.55 EPS for the current year.

Insider Activity

In related news, CFO Mark Ragosa sold 17,845 shares of the firm’s stock in a transaction dated Monday, February 9th. The stock was sold at an average price of $43.28, for a total transaction of $772,331.60. Following the completion of the transaction, the chief financial officer directly owned 12,086 shares in the company, valued at $523,082.08. This trade represents a 59.62% decrease in their position. The sale was disclosed in a legal filing with the SEC, which is available through this link. Also, Director Barry D. Quart sold 2,690 shares of Kiniksa Pharmaceuticals International stock in a transaction dated Thursday, February 12th. The shares were sold at an average price of $45.00, for a total value of $121,050.00. Following the completion of the transaction, the director directly owned 12,546 shares of the company’s stock, valued at approximately $564,570. This represents a 17.66% decrease in their ownership of the stock. Additional details regarding this sale are available in the official SEC disclosure. Over the last ninety days, insiders sold 123,623 shares of company stock valued at $5,236,389. 53.48% of the stock is currently owned by corporate insiders.

Institutional Inflows and Outflows

Several hedge funds and other institutional investors have recently made changes to their positions in the business. Arrowstreet Capital Limited Partnership acquired a new position in shares of Kiniksa Pharmaceuticals International in the second quarter valued at approximately $20,349,000. Qube Research & Technologies Ltd grew its stake in shares of Kiniksa Pharmaceuticals International by 277.8% in the second quarter. Qube Research & Technologies Ltd now owns 888,364 shares of the company’s stock worth $24,581,000 after acquiring an additional 653,236 shares in the last quarter. Rubric Capital Management LP increased its position in shares of Kiniksa Pharmaceuticals International by 15.6% during the second quarter. Rubric Capital Management LP now owns 3,909,806 shares of the company’s stock worth $108,184,000 after acquiring an additional 526,567 shares during the period. Cubist Systematic Strategies LLC raised its stake in shares of Kiniksa Pharmaceuticals International by 213.2% in the second quarter. Cubist Systematic Strategies LLC now owns 657,475 shares of the company’s stock valued at $18,192,000 after acquiring an additional 447,536 shares in the last quarter. Finally, Spruce Street Capital LP purchased a new position in Kiniksa Pharmaceuticals International in the fourth quarter valued at $17,943,000. Hedge funds and other institutional investors own 53.95% of the company’s stock.

Kiniksa Pharmaceuticals International Company Profile

Kiniksa Pharmaceuticals International, Inc is a biopharmaceutical company focused on discovering, acquiring and developing therapeutics for patients suffering from lifethreatening and debilitating immune-mediated diseases. Founded in 2013 and headquartered in Lexington, Massachusetts, Kiniksa applies a patient-centric approach to build a diversified portfolio of marketed medicines and clinical-stage candidates targeting inflammation and immunology. The company’s core mission is to address complex conditions with significant unmet medical needs by advancing both novel and differentiated therapies.

The company’s lead marketed product is Ilaris (canakinumab), an interleukin-1β blocker licensed for the treatment of cryopyrin-associated periodic syndromes, systemic juvenile idiopathic arthritis, adult-onset Still’s disease and Schnitzler syndrome.